Buried in exon 2 of CYP1A2 lies a single nucleotide change that can reduce the enzyme's activity to less than 1% of normal. The rs72547511 variant — replacing the amino acid proline with arginine at position 42 of the protein — is rare but clinically consequential for anyone who carries it and takes medications that depend on CYP1A2 for clearance.

CYP1A2¹¹ CYP1A2
CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2) is the dominant hepatic enzyme for metabolizing caffeine, theophylline, clozapine, olanzapine, tizanidine, and melatonin. Together, CYP1A2 accounts for roughly 95% of caffeine clearance and a large fraction of several psychiatric medication pathways.

The Mechanism

Proline at position 42 sits in the N-terminal transmembrane anchor of CYP1A2, a region critical for correct membrane insertion and subsequent hemoprotein[| hemoprotein: a protein containing a heme iron group, essential for the oxidative chemistry CYP enzymes perform] folding. When arginine replaces proline, the structural rigidity provided by proline's cyclic sidechain is lost, and the resulting protein fails to properly incorporate its heme iron center.

Saito et al. (2005)²² Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 expressed the Pro42Arg variant in Chinese hamster V79 cells and measured reduced CO difference spectra — a direct measure of functional hemoprotein formation. The peak at 450 nm characteristic of active CYP enzyme was barely detectable in the Pro42Arg variant, despite protein expression at ~66% of wild-type levels. Catalytic efficiency (Vmax/Km) for 7-ethoxyresorufin O-deethylation was less than 1% of wild type; phenacetin O-deethylation was similarly abolished. The researchers concluded that Pro42 is a critical residue for producing catalytically active CYP1A2.

The Evidence

The Pro42Arg change is catalogued as the CYP1A2*15 allele. Ito et al. (2015)³³ Ito et al. (2015)
Ito M et al. Functional characterization of 20 allelic variants of CYP1A2. Drug Metab Pharmacokinet, 2015 confirmed CYP1A2*15 belongs to the group of variants with inactive or near-absent enzymatic function, alongside *4, *6, *8, *16, and *21.

For clozapine — an antipsychotic with a narrow therapeutic window[| narrow therapeutic window: the dose range between efficacy and toxicity is small, so small PK changes matter greatly] — Kappel et al. (2024)⁴⁴ Kappel et al. (2024)
Kappel DB et al. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. Eur Neuropsychopharmacol, 2024 found that rare loss-of-function CYP1A2 variants collectively had the strongest pharmacogenomic effect of any gene on clozapine metabolism (β = 0.324, p = 0.009). Carriers of rare no-function alleles showed substantially elevated dose-adjusted clozapine concentrations.

A systematic review and meta-analysis by Santes-Palacios et al. (2018)⁵⁵ systematic review and meta-analysis by Santes-Palacios et al. (2018)
Santes-Palacios R et al. The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. Pharmacogenomics J, 2018 confirmed the importance of CYP1A2 genetic variation for inter-individual differences in drug clearance, though most studies focus on the common rs762551 variant. Rare coding variants like Pro42Arg have larger per-allele effects but lower population impact due to their rarity.

Practical Actions

This variant's rarity means most people will never encounter it. For those who carry one copy: caffeine half-life can extend significantly — a morning coffee may still be clearing at bedtime. For CYP1A2-metabolized medications, standard doses can produce plasma concentrations well above therapeutic targets. Prescribers should be aware when treating carriers with theophylline (asthma, COPD), clozapine or olanzapine (schizophrenia), or tizanidine (spasticity/muscle spasm).

A note on the second alternate allele: rs72547511 is multiallelic — the C>T change at the same position produces Pro42Leu. This variant has not been functionally characterized in the published literature as of the research date, but given that Pro42 is structurally critical, Pro42Leu likely also impairs CYP1A2 function.

Interactions

Carriers of rs72547511 (CYP1A2*15) who are also homozygous for the rs762551 C allele (slow inducibility) face a compounded reduction: one allele near-absent in activity, the other with reduced inducibility. For drugs like clozapine, this combination could produce clozapine levels equivalent to those seen during CYP1A2 inhibitor co-administration (e.g., ciprofloxacin, fluvoxamine), both of which are associated with toxic clozapine concentrations in case reports.

When the immune system encounters a harmless pollen grain or a cat hair, the difference between a calm non-reaction and a full allergic cascade often begins at the cell surface, where receptor proteins decide whether to escalate or stand down. The IL1RL1/IL18R1 gene cluster on chromosome 2q12 encodes two closely related interleukin receptors — IL1RL1 (also called ST2)¹¹ IL1RL1 (also called ST2)
ST2 is the receptor for IL-33, a cytokine released by barrier epithelium during physical stress or allergen exposure. IL-33 signals through ST2 to activate type 2 immune responses, mast cells, and ILC2 cells and IL18R1 (the IL-18 receptor)²² IL18R1 (the IL-18 receptor)
IL-18 is an inflammasome-derived cytokine with context-dependent roles: it promotes Th1 anti-viral immunity but can amplify Th2-driven allergy when chronically elevated; IL18R1 is expressed on T cells, NK cells, and innate lymphoid cells — that together calibrate how strongly the immune system responds to inhaled and ingested allergens. The rs72823628 variant sits within an intron of IL1RL1 at position 102,312,157 on GRCh38, roughly 43 kb upstream of IL18R1. As a regulatory intronic variant, it most likely influences gene expression or mRNA processing rather than protein structure.

The Mechanism

IL1RL1 (ST2) is the surface receptor for IL-33, an alarmin cytokine rapidly released by airway epithelial cells and skin keratinocytes when damaged by allergens, pollutants, or mechanical stress. IL-33/ST2 signaling activates type 2 innate lymphoid cells (ILC2s)³³ type 2 innate lymphoid cells (ILC2s)
ILC2s are tissue-resident immune cells that amplify allergic inflammation without requiring prior antigen sensitization; they produce IL-4, IL-5, and IL-13, driving eosinophil recruitment and IgE production, mast cells, and basophils, producing the cytokines (IL-4, IL-5, IL-13) that define allergic inflammation. The intronic rs72823628 variant likely modifies IL1RL1 expression levels in these immune cells, altering the magnitude of IL-33-triggered responses. Variants in this locus have been shown to affect the ratio of soluble (sST2, a decoy receptor that quenches IL-33 signaling) to membrane-bound ST2, with regulatory alleles shifting this balance. Carriers of the A allele appear to have a configuration that reduces net IL-33 signaling amplitude, dampening the immune response to allergens.

The adjacent IL18R1 gene encodes the receptor for IL-18, an inflammasome-derived cytokine that bridges innate and adaptive immunity. In the context of allergic disease, IL-18 modulates both Th1-suppressive and Th2-amplifying pathways depending on the cytokine milieu. Genetic variation across the IL1RL1/IL18R1 cluster influences both arms of this response; rs72823628 may tag regulatory variation that affects the expression of one or both receptors in airway-relevant tissues.

The Evidence

The IL1RL1/IL18R1 locus on chromosome 2q12 is one of the most robustly replicated genetic associations with allergic and atopic disease. The GABRIEL Consortium GWAS⁴⁴ GABRIEL Consortium GWAS
Moffatt et al. 2010 — 10,365 asthma cases and 16,110 controls; rs3771166 at the IL1RL1/IL18R1 locus reached P=3×10⁻⁹ for asthma established this locus at genome-wide significance for asthma. The Ferreira 2017 analysis⁵⁵ Ferreira 2017 analysis
360,838 participants; 136 independent risk variants identified for asthma, hay fever, and eczema combined; the IL1RL1/IL18R1 region among the most consistently replicated loci across all three allergic conditions extended the association to all three major atopic diseases — asthma, allergic rhinitis (hay fever), and eczema — confirming shared genetic architecture.

For rs72823628 specifically, a 2022 case-control study in the Chinese Han population⁶⁶ 2022 case-control study in the Chinese Han population
Li et al. 2022 — 1,000 allergic rhinitis patients and 1,000 controls; genotyping by Agena MassARRAY; stratified analysis by sex found that the A allele was significantly associated with reduced allergic rhinitis risk. The protective effect was most pronounced in male participants. The IL33–IL1RL1 pathway analysis by Savenije et al. 2014⁷⁷ Savenije et al. 2014
PIAMA cohort (n=2,007) and ALSPAC cohort (n=7,247); intermediate-onset wheeze showed strongest IL33/IL1RL1 pathway associations, suggesting these variants influence the timing of allergic sensitization further refined the picture, showing that IL1RL1/IL18R1 variants particularly influence intermediate-onset wheezing — the phenotype most closely linked to allergic sensitization — rather than early transient or late non-atopic wheeze. This pattern supports the interpretation that rs72823628 modifies not simply whether allergic disease occurs but when sensitization first takes hold.

The A allele frequency shows striking population variation: ~21% in Africans, ~14% in Europeans, ~13% in East Asians, and only ~3% in South Asians. This variation means protection is distributed very unevenly across ancestries, with South Asian populations carrying the highest prevalence of the susceptibility (GG) genotype.

Practical Actions

The G allele (standard genotype) does not indicate disease — the majority of people carry GG and do not develop clinical allergic disease. However, the GG genotype lacks the reduced IL-33 signaling associated with the A allele, meaning the allergic response threshold is set at the population-average level. For people who do develop allergic symptoms, this knowledge supports earlier evaluation rather than watchful waiting, since genetic susceptibility at this locus predates sensitization.

Carriers of at least one A allele (AG or AA) carry a partial or full protective effect against allergen sensitization through dampened IL-33/ST2 signaling. This does not confer immunity to allergic disease but shifts the threshold upward — a meaningful difference in high-allergen environments or in families with strong atopic history.

Interactions

The IL1RL1/IL18R1 locus works in concert with the upstream IL-33 ligand gene. The variant rs1342326 near IL33 (identified at P=9×10⁻¹⁰ in the GABRIEL asthma GWAS) represents the other end of the signaling axis: IL-33 as the danger signal, IL1RL1/ST2 as the receptor. Individuals who carry both higher IL-33 production alleles (IL33 locus) and standard-susceptibility alleles at IL1RL1 (GG at rs72823628) may experience amplified allergic signaling from both ends of the pathway — a compound effect worth considering if allergy history is strong. The interaction between IL33 and IL1RL1 variant combinations has been examined in the Savenije 2014 study, which identified SNP pair interactions for childhood asthma phenotypes.

CACNA2D3 encodes the alpha-2-delta-3 subunit of voltage-gated calcium channels, a critical regulator of how pain signals travel from the thalamus¹¹ thalamus
the brain's sensory relay station to higher cortical pain centers. Unlike many pain genes that act in peripheral nerves,

CACNA2D3 operates centrally — in the thalamus, cortex, hippocampus, and cerebellum, but not in the spinal cord or dorsal root ganglia . This intronic variant sits in a regulatory region that influences how effectively your brain amplifies or dampens incoming pain signals.

The Mechanism

The alpha-2-delta-3 protein regulates the trafficking and surface expression of voltage-gated calcium channel complexes, which in turn modulate synaptic transmission and function .

The protein's MIDAS motif binds divalent metal cations and promotes trafficking of calcium channel subunits to the plasma membrane, leading to an 80% increase in neurotransmitter release probability . The rs6777055 variant affects this regulatory machinery in a region-specific manner.

Functional imaging studies reveal the consequences: loss of CACNA2D3 function results in impaired transmission of noxious heat-evoked signals from the thalamus to higher pain centers such as the sensory and motor cortices, as well as impaired intracortical inhibition . The protective C allele appears to reduce channel function, creating a partial block in pain signal propagation at the thalamic level — your brain's sensory gatekeeper.

The Evidence

Neely et al. (2010) studied 189 healthy volunteers and found that the minor C allele of rs6777055 was significantly associated with reduced acute thermal pain sensitivity. Among 169 Caucasian adults with chronic lumbar root pain from disc herniation, carriers of the minor C allele experienced independently less pain within the first year following surgery . The association showed a recessive pattern²² The association showed a recessive pattern
meaning two copies of C were needed for the full protective effect.

The C allele frequency was 0.2 in the studied population, meaning approximately 4% of people are homozygous CC

— a rare but meaningful protective genotype.

Mouse knockout studies confirmed the mechanism: Cacna2d3-null mice showed impaired thermal sensitization, diminished pain responsiveness, and delayed inflammatory heat hyperalgesia .

Intriguingly,

CACNA2D3 mutations also affect sensory filtering more broadly — zebrafish with cacna2d3 mutations show increased startle sensitivity to acoustic stimuli and impaired habituation learning, a process disrupted in human CNS disorders including ADHD, schizophrenia, and autism .

Loss-of-function mutations in CACNA2D3 have been recently identified as pathogenic for non-syndromic autism spectrum disorder in humans .

Practical Implications

If you carry two copies of the common A allele (AA genotype), your calcium channels function normally, transmitting pain signals efficiently from thalamus to cortex. This is the typical human experience — appropriate pain sensitivity that serves its protective function. If you have one C allele (AC), you may have slightly reduced pain sensitivity, particularly to thermal stimuli and in chronic pain contexts after injury or surgery. The recessive inheritance pattern means the effect is modest with just one copy.

The CC genotype confers meaningful protection: reduced acute thermal pain sensitivity and less chronic pain following surgical intervention for disc herniation. This isn't complete pain insensitivity — rather, it's a recalibration of the gain on pain signals at the thalamic gate.

The variant affects transmission from the thalamus to cortex rather than blocking pain responses in sensory neurons themselves , so basic protective pain reflexes remain intact.

Importantly, this isn't a "better" or "worse" genotype — it's a trade-off.

The same gene variants that reduce pain sensitivity also affect other forms of sensory processing, potentially increasing sensitivity to acoustic stimuli and impairing habituation to repeated sensory input . The AA genotype maintains standard pain sensitivity and sensory filtering, while CC trades some pain sensitivity for altered sensory gating more broadly.

Interactions

CACNA2D3 rs6777055 interacts with rs1851048, another CACNA2D3 variant that was independently associated with reduced post-surgical pain in the Neely et al. study. Both variants likely affect the same underlying mechanism — calcium channel trafficking and function in thalamic pain circuits — but may do so through different regulatory pathways or in different neuronal populations.

The broader CACNA2D family is clinically important:

CACNA2D1 and CACNA2D2 are the molecular targets of gabapentin and pregabalin, potent medications for neuropathic pain and epilepsy . However,

CACNA2D3 does not bind gabapentin , so your rs6777055 genotype won't predict response to these drugs. CACNA2D3 instead affects the intrinsic pain processing architecture of your brain.

Given the gene's role in sensory filtering and its links to autism and ADHD, rs6777055 genotype may interact with variants in other sensory processing genes (such as those affecting GABAergic interneurons in prefrontal cortex) to influence overall sensory sensitivity, though these interactions haven't been systematically studied.

CYP1A2 is the liver enzyme responsible for clearing approximately 95% of the caffeine you consume, along with clinically critical medications including the muscle relaxant tizanidine, the antipsychotic clozapine, the bronchodilator theophylline, and the antidepressant melatonin. The rs72547515 variant, catalogued as the [CYP1A2*16 star allele | Star alleles are named variants in drug-metabolizing genes that define activity level; *16 denotes a severely reduced-function allele], carries a missense substitution at codon 377 that converts arginine to glutamine (Arg377Gln, c.1130G>A). This change nearly abolishes enzymatic activity.

The Mechanism

Arginine-377 sits within a structurally critical region of the CYP1A2 protein. Saito et al. (2005)¹¹ Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 showed that the Arg377Gln substitution reduces CYP1A2 protein expression to approximately 30% of wild-type, and — more significantly — increases the Km (substrate binding constant) approximately 9-fold while reducing Vmax to less than 3% and intrinsic clearance (Vmax/Km) to less than 1% of the wild-type enzyme. The authors concluded that Arg377 is a critical residue for producing catalytically active CYP1A2 holoenzyme, likely required for correct protein folding and incorporation of the heme cofactor that drives oxidation chemistry. A subsequent study by Ito et al. (2015)²² Ito et al. (2015)
Ito M et al. Functional characterization of 20 allelic variants of CYP1A2. Drug Metab Pharmacokinet, 2015 characterizing 20 CYP1A2 alleles confirmed that CYP1A2*16 is inactive toward both phenacetin and 7-ethoxyresorufin — the two canonical CYP1A2 substrates used in functional assays.

The Evidence

The functional data for CYP1A2*16 are derived from recombinant expression systems rather than clinical pharmacokinetic studies, which is unsurprising given the extreme rarity of the allele (approximately 1–4 carriers per 10,000 people in Japanese cohorts, and even rarer globally). For CYP1A2 substrates, the pharmacokinetic consequences of near-complete enzyme inactivation are well-understood from drug interaction studies using CYP1A2 chemical inhibitors. For tizanidine, Backman et al. (2008)³³ Backman et al. (2008)
Backman JT et al. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol, 2008 demonstrated that even partial CYP1A2 suppression (via smoking cessation) raises tizanidine plasma levels substantially; a moderate CYP1A2 inhibitor (mexiletine) increased tizanidine peak concentration and area-under-the-curve significantly in a separate study (PMID 19789372). For theophylline, a narrow-therapeutic- index bronchodilator, CYP1A2 handles the majority of clearance — reduced enzyme function elevates plasma concentrations into the toxic range (arrhythmia, seizures). For caffeine, the half-life extends from approximately 4–6 hours in normal metabolizers to potentially 12–24+ hours when CYP1A2 is severely impaired.

The Dutch Pharmacogenetics Working Group (DPWG) reviewed CYP1A2 variants for clozapine and olanzapine in its 2023 guideline update and concluded that no dose adjustment is warranted solely on the basis of CYP1A2 genotype for these antipsychotics, citing lack of demonstrated pharmacokinetic effect in available studies. This conclusion was based on the more common polymorphisms (rs762551 and similar); it does not specifically evaluate the severely reduced-function *16 allele.

Practical Implications

Because rs72547515 is one of the rarest pharmacogenomic variants in the CYP1A2 gene, heterozygous carriers (AG) are the only clinically relevant genotype; homozygous AA individuals are essentially non-existent in population data. A single copy of the *16 allele reduces overall CYP1A2 capacity partially — the remaining wild-type allele continues to produce functional enzyme, but total metabolic throughput is reduced. The practical impact is most significant when CYP1A2-metabolized drugs are prescribed at standard doses, or when multiple CYP1A2 substrates are used simultaneously.

Carriers should inform prescribers before starting tizanidine (muscle relaxant), theophylline or aminophylline (asthma/COPD), or any other narrow-therapeutic- index CYP1A2 substrate. Therapeutic drug monitoring (plasma level measurement) is a straightforward risk-reduction strategy for drugs with established target ranges.

Interactions

CYP1A2 activity is strongly modulated by inducers (cigarette smoke, charcoal- grilled meat, omeprazole, cruciferous vegetables) and inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives, vemurafenib). For a carrier of the *16 allele, starting a strong CYP1A2 inhibitor like fluvoxamine on top of a reduced-function allele creates additive suppression; starting an inducer might partially compensate. The common CYP1A2 variant rs762551 (*1F) acts via inducibility — its effect is modified by smoking; the *16 variant is a structural (protein-level) defect that inducers cannot overcome. Carriers should be aware that this variant interacts differently with environmental exposures than the more common CYP1A2 regulatory polymorphisms.

On chromosome 11q13.5, a single regulatory variant, rs7927894, sits near one of the most consequential genes in allergic disease genetics. The T allele at this position raises expression of EMSY¹¹ EMSY
EMSY (C11orf30) is a chromatin-associated protein that epigenetically silences gene expression by recruiting histone-modifying complexes; it was first described as a BRCA2-interacting protein amplified in breast and ovarian cancer — and higher EMSY activity turns down the genes that build and maintain the skin's waterproof barrier. This locus is the broadest-acting allergic disease susceptibility signal in the human genome, influencing risk for eczema, asthma, hay fever, and the progressive atopic march from early childhood eczema to later-onset respiratory and food allergies.

The Mechanism

EMSY is a chromatin regulatory protein that acts as a transcriptional repressor. It binds chromatin-modifying complexes and silences nearby target genes by altering histone modifications at their promoters. In skin, EMSY's key targets include genes encoding filaggrin²² filaggrin
Filaggrin (FLG) is a structural protein that aggregates keratin filaments in the outermost skin layer and is broken down into natural moisturising factors; loss-of-function FLG mutations are the strongest known single-gene risk factor for eczema, filaggrin-2, and enzymes that synthesise long-chain ceramides — the lipid molecules that seal the space between skin cells and prevent water loss and allergen entry.

Mechanistic studies³³ Mechanistic studies
Elias MS, Brown SJ, J Allergy Clin Immunol 2019 — siRNA knockdown and overexpression experiments in organotypic skin models directly demonstrated that reducing EMSY activity enhances barrier development: filaggrin, filaggrin-2, and long-chain ceramide levels all increase when EMSY is silenced. Conversely, overexpression of EMSY reduces these same barrier markers. In skin biopsy samples from atopic dermatitis patients, EMSY nuclear staining is increased compared with non-atopic controls, consistent with a gain-of-repression model: the rs7927894 T allele drives higher EMSY expression, which suppresses barrier gene transcription, which compromises the skin's physical defences and permits allergen sensitisation. A second nearby gene, LRRC32 (encoding GARP), lies within the same topologically associating domain and has independently been linked to atopic dermatitis through its role in regulatory T-cell activation and TGF-β signalling, suggesting this locus has at least two distinct mechanisms converging on allergic susceptibility.

The Evidence

rs7927894 was identified in a 2009 genome-wide scan⁴⁴ 2009 genome-wide scan
Esparza-Gordillo et al., Nat Genet — 939 cases and 975 controls in discovery, 2,637 cases and 3,957 controls in replication across European cohorts as the primary GWAS hit for atopic dermatitis at 11q13.5 (combined p=7.6×10⁻¹⁰). Homozygous T allele carriers (TT) had an odds ratio of 1.47 for atopic dermatitis compared with CC individuals; heterozygous CT carriers had intermediate risk consistent with additive inheritance.

The locus has been replicated across multiple independent cohorts. A large meta-GWAS⁵⁵ large meta-GWAS
Paternoster et al., Nat Genet 2011 — discovery cohort 5,606 affected individuals and 20,565 controls, replication 5,419 and 19,833 confirmed the 11q13.5 locus signal. In the 9,300-participant ALSPAC birth cohort⁶⁶ 9,300-participant ALSPAC birth cohort
Marenholz et al., Hum Mol Genet 2011 — prospective UK birth cohort with longitudinal phenotyping of atopic conditions, the T allele was associated not only with eczema but also with atopic asthma and hay fever, with the strongest effects seen in combined phenotypes: eczema plus asthma (OR=1.50) and eczema plus hay fever (OR=1.37). The population attributable risk fraction was estimated at 9.3% for eczema and approximately 25% for eczema-associated asthma or hay fever — a substantial contribution from a single common variant.

A 2015 meta-analysis⁷⁷ 2015 meta-analysis
Marenholz et al., Nat Commun — 12 populations, 2,428 combined eczema+asthma cases and 17,034 controls confirmed C11orf30/LRRC32 as one of seven loci contributing to the atopic march. The Polish ECAP cohort study⁸⁸ Polish ECAP cohort study
Ponińska et al., PLoS One 2017 found that the T allele was associated with atopic dermatitis (OR=1.39) and persistent allergic rhinitis (OR=1.24) in a haplotype-dependent manner, with the effect restricted to haplotypes also encoding G at rs7125552.

The interaction with filaggrin mutations⁹⁹ filaggrin mutations
O'Regan et al., J Allergy Clin Immunol 2010 — 511 Irish pediatric eczema cases and 1,000 controls; FLG mutations carried OR=5.81 is particularly clinically important. The rs7927894 T allele effect is independent of and additive with FLG mutations. In a paediatric Polish cohort¹⁰¹⁰ paediatric Polish cohort
Dębińska et al., Postepy Dermatol Alergol 2020 — 188 children under 2 years, carrying both the T allele and a filaggrin loss-of-function mutation raised atopic dermatitis odds to OR=16.41 — far exceeding the effect of either variant alone.

Practical Actions

The EMSY T allele acts upstream of filaggrin and ceramide production. This means carriers have a genetically reduced capacity to maintain the skin barrier — even without carrying FLG loss-of-function mutations. The practical priority is barrier support and early recognition of atopic progression.

Ceramide-containing emollient therapy is the most mechanistically specific intervention for EMSY T allele carriers: since the risk operates partly by reducing ceramide synthesis, topical ceramide replacement directly addresses the underlying deficit. For established atopic dermatitis, regular application of ceramide-dominant emollients helps restore barrier integrity and reduce itch and inflammation severity. This is distinct from the question of emollient use in newborns for primary prevention — randomised trial evidence (BEEP trial, PMID 32087126) does not support daily emollient in infancy as a primary prevention strategy for eczema in high-risk infants and found no benefit alongside some increase in skin infection risk.

Early allergen introduction during weaning (4–6 months) significantly reduces food allergy risk in infants with eczema (peanut: LEAP trial, PMID 25705822 — 86% relative risk reduction in high-risk infants). Since rs7927894 T allele carriers are at elevated risk for the full atopic march — including food allergy as part of allergen sensitisation through barrier breach — early diversified allergen introduction is a priority management strategy.

Interactions

The most clinically important interaction is with filaggrin (FLG) loss-of-function variants (rs61816766, rs12123821 and others). Both loci converge on the same biological pathway — epithelial barrier maintenance — but through different mechanisms: FLG directly encodes the barrier structural protein, while EMSY regulates its transcription. When both vulnerabilities co-occur, barrier dysfunction is substantially amplified (OR exceeding 16 in paediatric cohorts). The combination is a strong candidate for a compound action.

The IL13 variant rs20541 (Arg130Gln) operates on the same allergic phenotype from the immune activation side, and the STAT3 variant rs17881320 influences downstream Th2 signalling. The 11q13.5 locus also physically co-localises with LRRC32/GARP, which independently affects regulatory T-cell function through TGF-β — a second mechanism at the same genomic address that compounds this locus's influence on allergic sensitisation.

The serotonin system runs through almost every aspect of headache biology. One of its receptors, the 5-HT1F receptor¹¹ 5-HT1F receptor
encoded by the HTR1F gene on chromosome 3, expressed in trigeminal neurons and brainstem pain-modulation nuclei, sits at the exact intersection of genetic migraine susceptibility and modern pharmacology. HTR1F is the direct molecular target of lasmiditan (Reyvow), the first FDA-approved ditan-class²² ditan-class
a new category of migraine drug distinct from triptans — same serotonin pathway, different receptor subtype, no vasoconstriction migraine medication. The variant rs6795209, located in the HTR1F genomic region, links your migraine susceptibility directly to this pharmacological target.

The Mechanism

HTR1F encodes a G protein-coupled receptor that, when activated by serotonin or by synthetic agonists like lasmiditan, inhibits adenylate cyclase and reduces neuronal firing. In the context of migraine, 5-HT1F receptor activation in trigeminal ganglia³³ trigeminal ganglia
clusters of pain-sensing neurons that innervate the head, meninges, and blood vessels; their aberrant activation is the proximate cause of migraine pain and brainstem nuclei suppresses the trigeminovascular cascade — the chain of events that generates the throbbing head pain, nausea, and light sensitivity of a migraine attack. Unlike triptans (which act on 5-HT1B and 5-HT1D receptors and cause vasoconstriction), 5-HT1F has no expression in vascular smooth muscle, making lasmiditan effective without cardiovascular risk — a critical distinction for the millions of migraineurs who also have hypertension, coronary artery disease, or prior stroke.

rs6795209 is an intergenic variant 3.3 kb downstream of C3orf38 and approximately 167 kb downstream of the HTR1F coding sequence. Like most GWAS tag SNPs, it likely acts as a regulatory marker — in linkage disequilibrium with functional variants that alter HTR1F expression levels in trigeminal or brainstem tissue rather than changing the protein sequence. The A allele (GRCh38 reference, population minor) is the risk allele: carrying one or two copies increases migraine susceptibility by tagging a haplotype associated with subtly altered HTR1F expression.

The Evidence

The primary evidence comes from Hautakangas et al. 2022⁴⁴ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, the largest migraine GWAS to date. The study analysed 102,084 migraine cases and 771,257 controls, identifying 123 risk loci. The rs6795209 A allele reached genome-wide significance at the HTR1F locus with OR = 1.042 (95% CI 1.03–1.06, p = 1×10⁻⁸) — a modest but well-powered effect consistent with the polygenic architecture of migraine. HTR1F was explicitly highlighted in the paper as a pharmacologically important locus because it is the target of lasmiditan, establishing a direct line from genetic epidemiology to clinical pharmacology.

The pharmacological case for HTR1F rests on large Phase 3 trials. Goadsby et al. 2019⁵⁵ Goadsby et al. 2019
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain demonstrated pain freedom at 2 hours in 31.4% (100 mg) and 38.8% (200 mg) of lasmiditan-treated patients versus 21.3% on placebo (p<0.001 for both doses, n=2,583 safety population). This confirmed that selective 5-HT1F agonism is an effective, vasoconstriction-free mechanism for acute migraine — validating HTR1F as a true therapeutic target and making GWAS hits at this locus clinically meaningful.

The effect size at rs6795209 (OR 1.042) is typical of common GWAS variants — this is one of many loci collectively contributing to migraine heritability, not a single deterministic mutation. Population frequency of the risk A allele is approximately 19% globally, somewhat lower in European populations (~15%) and higher in African populations (~36%).

Practical Actions

For A allele carriers: migraine is substantially polygenic, and a single variant with OR 1.042 explains only a fraction of individual risk. The clinical relevance of rs6795209 is primarily pharmacological — it flags that the HTR1F pathway is genetically implicated in your migraine biology, which has direct implications if you suffer from migraines and are choosing acute treatments, particularly if triptans are contraindicated due to cardiovascular risk.

For all migraine sufferers regardless of genotype: lasmiditan's mechanism (selective 5-HT1F agonism) means it works through the exact pathway this locus tags. The drug does not require any specific genotype at rs6795209 to be effective — clinical trials enrolled unselected migraine patients — but the presence of this GWAS signal adds biological context for treatment choice discussions.

Interactions

Migraine is highly polygenic. rs6795209 at HTR1F represents one node in a network of 123+ risk loci identified by Hautakangas 2022. Other serotonin-system and trigeminovascular loci include rs10166942 (TRPM8, cold-pain sensitivity and migraine), rs1835740 (near MTDH/SLC2A9, migraine with aura), and rs2651899 (PRDM16, migraine and cardiovascular pleiotropy). Each adds an independent fractional contribution to migraine liability. Polygenic risk scoring across all migraine loci will ultimately be more clinically useful than individual locus interpretation, but HTR1F is notable because the gene is a validated pharmacological target.

CYP1A2 is one of the most abundant drug-metabolizing enzymes in the liver, responsible for breaking down approximately 10–15% of clinically used medications, including caffeine¹¹ caffeine
CYP1A2 processes ~95% of ingested caffeine, clozapine (antipsychotic), theophylline (asthma), olanzapine, tizanidine, and melatonin. The rs72547516 variant causes an isoleucine-to-valine substitution at position 386 of the CYP1A2 protein (p.Ile386Val), a missense change that may alter enzyme structure and reduce its metabolic capacity.

The Mechanism

The isoleucine at codon 386 sits within the substrate-binding region of CYP1A2. The Ile386Val substitution²² Ile386Val substitution
Valine's smaller side chain and slightly different steric profile may reduce the precision of substrate positioning or alter active-site geometry, affecting catalytic efficiency is predicted to reduce enzyme activity, though in-vivo data in large populations are lacking due to the variant's rarity. CYP1A2 is also highly inducible: cigarette smoke, charcoal-grilled meat, and cruciferous vegetables upregulate its expression via the aryl hydrocarbon receptor (AhR) pathway. Carriers of the G allele who are non-smokers would be expected to have reduced basal CYP1A2 activity, with limited compensatory induction.

The Evidence

This variant is extremely rare globally³³ extremely rare globally
G allele frequency 0.04–0.07% across major population databases; homozygous GG genotype essentially unobserved in population studies, with the highest observed frequencies in small Northern European cohorts (up to ~0.7% in Finnish samples and 2.5% in a small Danish sample). No ClinVar entry exists, and no CPIC or DPWG clinical guideline specifically addresses this variant.

The broader pharmacogenomics context is well-established: reduced CYP1A2 function, from any cause, leads to slower clearance of CYP1A2 substrates. A pathway-targeted pharmacogenomics study of 150 human liver samples⁴⁴ pathway-targeted pharmacogenomics study of 150 human liver samples
Klein K et al. Frontiers in Pharmacology, 2010 showed that genetic and environmental factors together explain about 42% of CYP1A2 activity variation, with both cis and trans regulatory polymorphisms contributing. Missense variants that alter active-site residues are classified as potentially impacting enzyme function in this framework.

The clinical relevance of CYP1A2 metabolizer status was demonstrated for caffeine and cardiovascular risk: Cornelis et al. (JAMA, 2006)⁵⁵ Cornelis et al. (JAMA, 2006)
Cornelis MC et al. Coffee, CYP1A2 Genotype, and Risk of Myocardial Infarction. JAMA, 2006 showed that slow metabolizers consuming 4+ cups of coffee daily had a 64% increased myocardial infarction risk (OR 1.64, 95% CI 1.14–2.34). For medications, CYP1A2 metabolizer status matters most for narrow-therapeutic-index drugs like clozapine and theophylline, where even a 30–50% reduction in clearance can push plasma concentrations into toxic ranges.

Practical Actions

If you carry the G allele (AG genotype), your CYP1A2 activity may be somewhat reduced compared to the AA majority. The most actionable steps involve monitoring drugs with narrow therapeutic windows, limiting caffeine especially if combining it with CYP1A2-inhibiting substances, and informing prescribers of your genotype before starting clozapine or theophylline.

CYP1A2 activity is strongly modifiable by lifestyle: smokers have 2–3× higher CYP1A2 induction, while cruciferous vegetables (broccoli, cabbage, Brussels sprouts) cause moderate induction. If you stop smoking, expect CYP1A2 activity to fall over several days, potentially raising levels of any CYP1A2-metabolized medications to clinical significance.

Interactions

The Ile386Val variant interacts with the well-characterized CYP1A2 inducibility variant rs762551 (*1F). Carriers of both the rs762551 slow-metabolizer C allele and this rs72547516 G allele could carry a compounded reduction in CYP1A2 baseline activity and inducibility, though this combination is expected to be vanishingly rare given the frequency of each allele. Smoking status is a major environmental modifier for both variants.

The C11orf30 gene — commonly known by its protein product name EMSY — sits at one of the most replicated and broadly acting loci in allergy genetics. Variants at this chromosome 11q13.5 locus have been found to influence risk for atopic dermatitis, asthma, hay fever, food allergy, poly-sensitization to multiple allergens, eosinophilic esophagitis, and inflammatory bowel disease. The rs7927997 variant is an expression quantitative trait locus (eQTL) that modulates EMSY transcript levels in both blood and intestinal tissue, making it a master regulator variant whose effects ripple across the entire atopic spectrum.

The Mechanism

EMSY is a transcriptional repressor¹¹ transcriptional repressor
EMSY silences gene expression by recruiting chromatin-remodeling complexes, including HP1-beta and histone methyltransferase components, to interferon-stimulated gene promoters. Its most important targets in the context of allergy are TSLP (thymic stromal lymphopoietin), a cytokine that acts as the master switch for type-2 allergic inflammation, and CCL5 (RANTES), a chemokine that recruits eosinophils, mast cells, and T helper-2 cells to sites of inflammation.

When EMSY is functioning normally at high levels, it keeps TSLP and CCL5 transcription suppressed in epithelial cells of the skin, esophagus, and gut. The rs7927997 T allele reduces EMSY expression in blood and intestinal tissue — and likely in epithelial barriers more broadly — releasing this brake. The result is elevated TSLP and CCL5 at mucosal surfaces²² elevated TSLP and CCL5 at mucosal surfaces
Fahey et al. 2018 Pediatric Allergy and Immunology (PMID 29663593) showed that EMSY overexpression in eosinophilic esophagitis tissue directly activates TSLP and CCL5 production, linking reduced EMSY repressor activity to eosinophil recruitment and mucosal inflammation, a state that primes dendritic cells and innate lymphoid cells (ILC2s) to initiate and sustain type-2 immune responses.

The rs7927997 T allele is intergenic, sitting in a regulatory region between C11orf30 and LRRC32 (which encodes GARP, a cell-surface docking molecule for TGF-β on regulatory T cells and platelets). Two independent functional signals have been identified at this locus: one regulating EMSY and one regulating LRRC32 expression, suggesting the region operates as a multi-gene regulatory hub for immune and barrier homeostasis.

The Evidence

The first genome-wide significant association at this locus for atopic disease came from a 2009 GWAS of atopic dermatitis³³ 2009 GWAS of atopic dermatitis
Esparza-Gordillo et al. Nature Genetics 2009; chromosome 11q13.5 rs7927894 (in high LD with rs7927997), OR 1.45, p=7.6×10⁻¹⁰ for eczema in European cohorts, identifying the C11orf30 region as the first reproducible non-FLG genetic risk factor for eczema. Approximately 13% of individuals of European descent are homozygous for the risk allele at this locus, carrying 1.45–1.47-fold elevated atopic dermatitis risk.

rs7927997 itself was identified in a landmark Crohn's disease GWAS meta-analysis of 6,333 cases and 15,056 controls⁴⁴ Crohn's disease GWAS meta-analysis of 6,333 cases and 15,056 controls
Franke et al. Nature Genetics 2010 — increased Crohn's disease susceptibility loci to 71; rs7927997 T allele OR 1.17, p=5.62×10⁻¹³, consistent with the growing recognition that EMSY variants influence both allergic and autoimmune-inflammatory gut disease through shared immune-regulatory pathways.

The eQTL function of rs7927997 was directly demonstrated by Di Narzo et al. 2016⁵⁵ Di Narzo et al. 2016
Blood and Intestine eQTLs from an Anti-TNF-Resistant Crohn's Disease Cohort; GWAS P = 6.0×10⁻¹³ for the rs7927997-C11orf30 eQTL signal in both blood and intestine, confirming that the T allele reduces EMSY transcript levels in disease-relevant tissues. Because EMSY is a transcriptional repressor of interferon-stimulated gene programs, this downregulation amplifies inflammatory gene expression in both gut and immune cells.

For the allergy side, a multi-centre European study Anto et al. 2015⁶⁶ Anto et al. 2015
C11orf30-rs2155219 (in LD with rs7927997) doubles risk of poly-sensitization; OR = 2.27 by skin prick test to 4+ allergens, p<0.05 demonstrated that the C11orf30 locus specifically amplifies sensitization breadth — the likelihood of reacting to multiple allergens simultaneously — rather than raising risk for any single allergy in isolation. This makes rs7927997 particularly relevant for individuals with multi-allergen profiles.

Practical Actions

Carriers of the T allele have a mildly elevated atopic burden at this locus, manifesting most noticeably as a tendency toward poly-sensitization, elevated IgE, and eosinophilic inflammation at mucosal surfaces (skin, gut, esophagus, airways). The actionable implications focus on: (1) monitoring eosinophil-related biomarkers if relevant symptoms are present, (2) optimizing epithelial barrier nutrition that supports TSLP suppression, and (3) considering anti-type-2 therapies if disease burden is clinically significant.

Interactions

rs7125552 (C11orf30/EMSY haplotype partner): The effect of the rs7927894 risk allele on atopic dermatitis is haplotype-dependent — rs7927894 T effect is significantly larger in individuals who also carry G at rs7125552 (a nearby haplotype partner). Since rs7927997, rs7927894, and rs7125552 all tag the same 11q13.5 regulatory block, compound carriership of risk haplotypes at this region produces additive atopic risk.

rs10751659 (PRG3): PRG3 encodes a paralog of eosinophil major basic protein (MBP) at the same allergy-expansion batch. Eosinophil infiltration at mucosal surfaces — driven in part by the TSLP/CCL5 axis regulated by EMSY — is the primary cytotoxic mechanism these granule proteins execute. Concurrent risk alleles at PRG3 and EMSY represent upstream (recruitment signal) and downstream (effector protein) components of the same eosinophilic damage pathway.

rs2476601 (PTPN22): PTPN22 encodes a phosphatase that brakes T-cell and B-cell activation; its R620W risk allele reduces regulatory T-cell braking. EMSY loss of function (T allele) and PTPN22 R620W loss of T-cell regulation represent parallel mechanisms that simultaneously amplify the type-2 immune response, potentially compounding atopic disease severity.

Motion sickness is not simply a matter of willpower. The nausea, cold sweats, and vomiting triggered by travel in cars, boats, or aircraft have a substantial heritable component — twin studies estimate heritability at around 57–70%. The first genome-wide association study of motion sickness, published by Hromatka et al. in 2015 using 80,494 participants from the 23andMe database¹¹ 80,494 participants from the 23andMe database
Hromatka BS et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, 2015, identified 35 loci at genome-wide significance. Among them, rs6833641 — a variant near the ARAP2 gene²² ARAP2 gene
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2; a multidomain GTPase-activating protein that regulates Arf6-mediated integrin trafficking, focal adhesion dynamics, and endosomal sorting, with notable expression in brain and inner ear tissues on chromosome 4p15.1 — achieved p=1.8×10⁻⁹ with a beta of +0.046 per G allele on a four-point severity scale.

What makes rs6833641 clinically distinctive is its dual association. Of the 35 motion sickness loci, only three also reached statistical significance for postoperative nausea and vomiting³³ postoperative nausea and vomiting
PONV is one of the most common surgical complications, affecting 20–30% of general surgical patients and up to 80% of high-risk groups; ondansetron prophylaxis is standard of care for high-risk patients (PONV). rs6833641 was one of them, with P=0.00101 and effect=0.09 for PONV in an independent surgical cohort. Motion sickness and PONV share overlapping neural circuitry involving the chemoreceptor trigger zone and the nucleus tractus solitarius — but a genetic variant that predicts both simultaneously is far more actionable than one predicting only the recreational nuisance.

The Mechanism

rs6833641 sits in an intergenic region approximately 66 kb upstream of the nearest gene annotation at this locus, in a region tagged as near ARAP2 in the GWAS. ARAP2 encodes a large multidomain protein containing ArfGAP, RhoGAP, ankyrin repeat, and five pleckstrin homology (PH) domains. Its primary catalytic activity is as an Arf6 GTPase-activating protein⁴⁴ Arf6 GTPase-activating protein
GTPases are molecular switches; GAPs (GTPase-activating proteins) accelerate GTP hydrolysis, switching the GTPase off. Arf6 controls membrane trafficking at the cell surface and endosomes, including recycling of integrins to focal adhesions. ARAP2 functions downstream of RhoA to regulate focal adhesion morphology, α5β1 integrin endosomal compartmentalisation, and actin cytoskeleton organisation. The gene is expressed in brain tissue (RPKM 5.8) and broadly across 22 additional tissues including the inner ear region.

The precise mechanism by which regulatory variation near ARAP2 modulates vestibular nausea circuits is not yet characterised. The Hromatka 2015 study points toward roles in inner ear development and neurological signal processing — both of which depend on the kind of membrane trafficking and cytoskeletal organisation that ARAP2 coordinates. rs6833641 likely acts as a regulatory variant that alters ARAP2 expression in relevant vestibular or brainstem neurons, but direct functional studies are lacking.

The Evidence

The primary evidence comes from Hromatka et al. 2015⁵⁵ Hromatka et al. 2015
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, the first and largest motion sickness GWAS, with 80,494 participants. The study used a validated four-point motion sickness severity scale and identified rs6833641 as a genome-wide significant hit (p=1.8×10⁻⁹). Each additional G allele was associated with a beta of +0.046 on the severity scale — a modest per-allele effect consistent with the polygenic architecture of motion sickness.

Critically, the study also tested all 35 motion sickness SNPs for association with PONV in an independent dataset. Of the 35 loci, only rs6833641, rs1195218 (near AUTS2), and rs6069325 (near CBLN4) reached significance for PONV as well. For rs6833641, the PONV association had p=0.00101 and effect=0.09. This cross-phenotype replication is important: it suggests that the neural pathways modulated by ARAP2-region variation contribute to emesis circuitry broadly, not just to vestibular-triggered symptoms.

The G allele — the risk allele — is the common allele, present in approximately 85% of the study population. This makes the C allele a protective minor variant, carried in usefully detectable frequency only in European populations (~7–15% C allele frequency; near-absent in East Asian, African, South Asian, and Latin American populations based on ALFA and 1000 Genomes data).

Practical Actions

For GG individuals (approximately 73% of the population): pre-surgical disclosure of motion sickness history to the anaesthesiology team is the most actionable implication. The genetic link between motion sickness susceptibility and PONV supports early prophylactic antiemetic administration — standard first-line agents include ondansetron (a 5-HT3 antagonist), dexamethasone, and scopolamine. In transit, GG carriers benefit from front-of-vehicle seating, horizon fixation, and prophylactic scopolamine patches or antihistamine premedication for predictable motion exposures.

For GC heterozygotes: partial G-allele dosage means intermediate susceptibility. The same pre-surgical disclosure applies, though PONV risk is statistically lower than in GG.

For CC individuals: the C allele is associated with reduced motion sickness susceptibility and the statistical PONV signal is attenuated.

Interactions

The dual motion sickness/PONV association at rs6833641 places it in the company of rs1195218 (near AUTS2, involved in neuronal development) and rs6069325 (near CBLN4, a cerebellin involved in synapse formation). These three loci likely converge on shared brainstem emesis circuitry — the chemoreceptor trigger zone and the area postrema. Whether carrying risk alleles at multiple loci compounds PONV risk additively has not been directly tested; the GWAS paper did not report interaction analyses for the three dual-association SNPs.

CYP1A2¹¹ CYP1A2
Cytochrome P450 family 1 subfamily A member 2 — the liver enzyme that processes about 95% of caffeine and several widely prescribed medications is one of the most clinically relevant drug-metabolizing enzymes in the body. The CYP1A2*8 allele (rs72547517) is a missense variant that substitutes histidine for arginine at position 456 of the enzyme (p.Arg456His), crippling the enzyme's ability to fold around its heme cofactor and carry out oxidative metabolism. This allele is extremely rare in most global populations but occurs at measurable frequency in Japanese and broader East Asian populations.

The Mechanism

Arginine-456 sits in a structurally critical region of the CYP1A2 protein. The substitution to histidine disrupts the tertiary folding required for heme incorporation — the spectral peak at 450 nm that defines an active cytochrome P450 enzyme is barely detectable in cells expressing the *8 variant. Without the iron-containing heme cofactor properly seated, the enzyme cannot perform the oxygen-insertion reactions that metabolize drugs and other substrates.

Saito et al. (2005)²² Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 expressed the *8 variant in Chinese hamster V79 cells and a baculovirus system, measuring its activity against [7-ethoxyresorufin | A standard CYP1A2 probe substrate used to assess oxidative activity in vitro] and phenacetin. The variant retained approximately 30% of wild-type protein expression but showed less than 3% of wild-type maximum velocity (Vmax), and less than 1% of the catalytic efficiency (Vmax/Km) — effectively a non-functional enzyme despite being present in the cell.

The Evidence

The functional characterisation by Saito et al. (2005)³³ Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 established CYP1A2*8 as a severe loss-of-function allele in vitro, with catalytic efficiency less than 1% of wild-type. This places it among the most functionally damaging CYP1A2 variants identified.

Population data from the 38KJPN Japanese genome project records the A allele at approximately 0.65% frequency (501/77,444 alleles), compared with near-zero frequency in European and African cohorts. The global TopMed frequency is ~0.005% (1 in 20,000 alleles). This extreme population stratification means the clinical relevance of *8 is almost entirely concentrated in East Asian individuals.

Because individuals carrying two *8 alleles (AA homozygotes) are expected to be vanishingly rare even in Japanese populations, the most clinically actionable scenario is a heterozygous carrier (AG) who also carries a second non-functional or reduced-function CYP1A2 allele — creating a compound heterozygous [poor metabolizer | Poor metabolizer (PM): both copies of the gene carry loss-of-function alleles, leaving the individual with minimal enzyme activity] state.

Practical Actions

CYP1A2 poor metabolizers have substantially reduced clearance of caffeine, theophylline, and certain psychiatric medications. The most clinically significant implications are:

Theophylline: a narrow therapeutic index bronchodilator where twofold differences in clearance can shift a patient from sub-therapeutic to toxic plasma levels. Poor metabolizers require lower doses and close plasma-level monitoring.

Clozapine and olanzapine: both antipsychotics are primarily cleared by CYP1A2. Poor metabolizers can accumulate several-fold higher plasma concentrations at standard doses, increasing the risk of sedation, QTc prolongation, and other dose-dependent adverse effects.

Caffeine: while not a medication safety issue for most people, the near-complete loss of CYP1A2 activity means caffeine is cleared extremely slowly, amplifying both its stimulant effects and its potential to disrupt sleep.

Carcinogen bioactivation: CYP1A2 activates [heterocyclic amines | Compounds formed in grilled and charred meats (e.g. PhIP, IQ) that require CYP1A2 activation to become DNA-damaging carcinogens] from grilled and charred meat into DNA-damaging intermediates. Reduced CYP1A2 activity in *8 carriers may alter their net carcinogen exposure from dietary sources, though the direction of effect depends on competing detoxification pathways.

Interactions

CYP1A2 activity is powerfully modified by environmental factors — tobacco smoke and cruciferous vegetables induce CYP1A2, while fluvoxamine, ciprofloxacin, and omeprazole inhibit it. These interactions act on top of the genetic baseline. A *8 carrier who also smokes will still have minimal enzyme activity because the structural basis for inducibility is eliminated by the missense change.

The common CYP1A2 regulatory variant rs762551 (*1F) acts through a completely different mechanism — inducibility — and does not compensate for the structural loss of function caused by *8. Carriers of both rs762551 C and rs72547517 A would have reduced inducibility compounded by structural loss of function on the *8 chromosome.